Elevated histone lactylation is crucial in the initiation and progression of various cancers. Although its role in breast cancer remains unconfirmed, the increased lactate release from enhanced glycolysis in triple-negative breast cancer (TNBC) suggests a potential link. In order to investigate the effect of histone lactylation on TNBC, we detected the lactate production and histone lactylation levels. Chromatin immunoprecipitation (ChIP) assay was used to confirm that minichromosome maintenance complex component (MCM) 7 is a downstream target. A variety of experimental techniques including, cell viability, colony formation assay, apoptosis assay, and transwell assay were used to describe the cell proliferation and migration ability. Histone lactylation levels were increased in TNBC tissues. Inhibiting lactate production suppressed the proliferation and migration of TNBC cells and histone lactylation in TNBC cells. Histone lactylation modulated MCM7 expression and translation, and MCM7 participated in histone lactylation regulation of TNBC cell function. These data show that enhanced glycolysis in TNBC cells results in increased lactate production, directly contributing to histone lactylation and subsequent activation of MCM7 promoter. Our results highlight that targeting the feedback loop involving glycolysis, lactate production, histone lactylation, and MCM7 transcription could be a therapeutic strategy for TNBC by inhibiting cell proliferation and migration.

Background While TRPA1 serves as a therapeutic target for nociceptive pain, its role in acute visceral pain induced by uterine cervical dilation (UCD) remains an enigma. This study aims to elucidate the upstream and downstream mechanisms of TRPA1 in the context of UCD-induced acute visceral pain. Methods The UCD rats were administered with SAH (inhibitor of the METTL3-METTL14 complex) via intrathecal tubing. Validate UCD model by measuring spinal c-Fos expression and EMG. The levels of TRPA1 and p-NR2B were evaluated by qRT-PCR and western blot，and m6A level was detected by the kit. RNA Immunoprecipitation was adopted to determine the binding between TRPA1 and METTL14. Neurons were isolated from rat dorsal root ganglia (DRG), exposed to SAH treatment, and subsequently subjected to actinomycin D experiments. Results In the UCD model, cervical dilation causes an increase in EMG signal and spinal cord c-Fos expression. At the same time, the levels of TRPA1, p-NR2B, METTL14, and m6A increased in a stimulus intensity-dependent manner. Intrathecal SAH, a METTL3-METTL14 inhibitor, alleviated UCD-induced pain and reversed above indicators. Further investigation revealed that METTL14 binds to TRPA1, increasing TRPA1 mRNA stability via m6A modification. Conclusion METTL14 stabilizes TRPA1 through m6A modification, thereby promoting NR2B phosphorylation, culminating in acute visceral pain induced by UCD.

This study used meta-analysis to examine the role of baseline absolute lymphocyte count (ALC) in the prognosis of advanced breast cancer (ABC) or metastatic breast cancer (MBC). A comprehensive search encompassing PubMed, The Cochrane Library, Embase, and Web of Science databases was undertaken to identify and screen literature based on predefined inclusion and exclusion criteria. Progression-free survival (PFS), time to treatment failure (TTF), post-progression survival (PPS), and overall survival (OS) were selected as outcome measures. A meta-analysis of 14 studies, involving 2,540 patients and employing Review Manager 5.3 and Stata 14.0, was conducted. Notably, 12 of these studies originated from Japan. The findings indicated that patients with ABC or MBC exhibiting high ALC had significantly improved PFS, TTF, PPS (hazard ratio [HR] = 0.53, 95% confidence interval [CI]: 0.45-0.62, P < 0.00001; HR = 0.57, 95% CI: 0.51-0.64, P < 0.00001), and OS (HR = 0.44, 95% CI: 0.33-0.58, P < 0.00001; HR = 0.68, 95% CI: 0.60-0.77, P < 0.00001) juxtaposed with low ALC individuals. These findings were corroborated by both univariate and multivariate analyses. Furthermore, subgroup analysis based on breast cancer subtype unveiled that high ALC was associated with prolonged PFS (HR = 0.35, 95% CI: 0.21-0.56, P < 0.0001), TTF, and PPS (HR = 0.45, 95% CI: 0.29-0.71, P = 0.0006) in both human epidermal growth factor receptor 2 (HER-2)-positive and -negative ABC or MBC patients. Additionally, high ALC correlated with prolonged OS in all BC subtypes (HR = 0.73, 95% CI: 0.61-0.88, P = 0.0008) and HER-2-negative ABC or MBC patients (HR = 0.65, 95% CI: 0.55-0.78, P < 0.00001). Subgroup analysis was conducted on chemotherapy regimens, with and without eribulin. Despite variations in chemotherapy regimens, patients with ABC or MBC and high ALC exhibited longer PFS and PPS (HR = 0.45, 95% CI: 0.30-0.67, P < 0.0001), PFS and TTF (HR = 0.39, 95% CI: 0.20-0.78, P = 0.008), and OS (HR = 0.71, 95% CI: 0.62-0.82, P < 0.00001; HR = 0.5, 95% CI: 0.35-0.70, P < 0.0001). The results of this meta-analysis suggest that baseline ALC, as an immune marker, can serve as an effective prognostic indicator for ABC or MBC.

Background: The predictive value of tumor-infiltrating lymphocytes (TILs) in response to neoadjuvant chemotherapy (NAC) for breast cancer (BC) has received increasing attention. Here, a meta-analysis was conducted to evaluate the correlation between the expression of stromal TILs and pathological complete response (pCR) after NAC in BC patients. Methods: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched online by using a combination of keywords and free words to screen literature on the expression of stromal TILs and pCR after NAC in patients with BC. The data were extracted and evaluated for quality. Relative risk (RR) was used to evaluate the relationship between the expression of stromal TILs before NAC and pCR in BC patients. Meta-analysis was performed with Review Manager 5.3 and STATA 14.0 software. Results: Eleven studies involving 6039 BC patients were included in the meta-analysis. The results showed a generally high expression of stromal TILs in BC patients, and the pCR rate after NAC in BC patients with a high expression of stromal TILs was significantly higher than that in BC patients with a low expression of stromal TILs [RR = 1.83, 95% confidence interval (CI): 1.69–1.97]. Subgroup analysis based on the molecular subtypes of BC showed that the pCR rate was significantly higher in patients with a high expression of stromal TILs in hormone receptor (HR)-positive BC [RR = 3.23, 95% CI: 2.43–4.30], human epidermal growth factor receptor 2 (HER-2)-positive BC [RR = 1.41, 95% CI: 1.25–1.60], and triple-negative BC [RR = 1.70, 95% CI: 1.53–1.90] than in those with a low expression of stromal TILs. Subgroup analysis based on expression threshold showed that the pCR rate was higher in patients with a high expression of stromal TILs than in patients with a low expression of stromal TILs at different expression thresholds (10% [RR = 1.99, 95% CI: 1.55–2.55], 20%/30% [RR = 1.57, 95% CI: 1.37–1.81], 50%/60% [RR = 1.91, 95% CI: 1.73–2.11]. Conclusion: TILs can be used as a predictor of pCR after NAC in patients with BC, and the appropriate high expression threshold of stromal TILs should be selected as the predictive value according to the molecular subtype of BC.

PurposeEpidural analgesia has emerged as a commonly used method for relieving labor pain. However, epidural-related maternal fever (ERMF) is characterized by a high occurrence rate and can have detrimental consequences for the well-being of both the mother and the fetus. This study aimed to investigate the functional role and underlying mechanism of dexmedetomidine (DEX) in ERMF.Materials and methodsRopivacaine (ROP)-induced human umbilical vein endothelial cells (HUVECs) were treated with DEX and/or transfected with ALKBH5 or FUNDC1 overexpression plasmid. qPCR and Western blot were adopted for mitophagy and pyroptosis marker protein detection. Autophagosomes were observed through electron microscopy, Caspase-1/PI double-positive cells were determined using flow cytometry. Inflammation-related factors were quantified using ELISA. The N6-methyladenosine (m6A) modification of FUNDC1 mRNA was examined using methylated RNA immunoprecipitation (MeRIP) and the binding between ALKBH5 and FUNDC1 mRNA was confirmed by RNA immunoprecipitation (RIP).ResultsIn ROP-induced HUVECs, there was a significant upregulation in ALKBH5 and FUNDC1, resulting in a notable increase in inflammation, pyroptosis, and mitophagy. The administration of DEX demonstrated the ability to alleviate ROP-induced pyroptosis and promote protective mitophagy. Interestingly, DEX treatment significantly reduced the interaction between ALKBH5 and FUNDC1 mRNA, while simultaneously increasing the m6A level of FUNDC1 mRNA in ROP-treated cells. Moreover, the overexpression of FUNDC1 partially reversed the effects of ALKBH5 overexpression on mitophagy and pyroptosis in HUVECs.ConclusionsDEX can promote mitophagy and inhibit pyroptosis through the ALKBH5/FUNDC1 axis in ERMF, indicating its potential as a therapeutic strategy for clinical ERMF treatment.

目的 探讨雄激素受体(AR)在三阴性乳腺癌(TNBC)中的表达及与预后的关系.方法 选取2018年9月1日至2022年5月31日在嘉兴市妇幼保健院乳腺科治疗的单侧无远处转移的TNBC患者98例为研究对象,其中AR表达的管腔雄激素受体(LAR)亚型38例,AR未表达的四阴性乳腺癌(QNBC)亚型60例.比较LAR亚型与QNBC亚型患者临床病理特征.同时对患者术后的生存情况进行随访,Kaplan-Meier生存曲线分析AR表达与术后无病生存期和总生存期的关系.结果 LAR亚型与QNBC亚型患者病灶直径、组织学分级、Ki-67、病理分期比较差异均有统计学意义(均P＜0.05).LAR亚型与QNBC亚型患者术后3年无病生存率(97.30％比94.30％)和总生存率(95.00％比100.00％)比较差异均无统计学意义(均P＞0.05).结论 AR表达与TNBC的病灶直径、组织学分级、Ki-67表达、病理分期有关,AR或许可以成为TNBC的预后指标及治疗靶点.

目的 分析1～2枚前哨淋巴结(SLN)宏转移且行乳房切除术的早期乳腺癌患者非前哨淋巴结(NSLN)转移的影响因素.方法 回顾性分析1～2枚SLN宏转移且行乳房切除术同时接受腋窝淋巴结清扫术(ALND)的123例早期乳腺癌患者的临床资料.根据有无NSLN转移分为未转移组(无NSLN转移,80例)和转移组(有NSLN转移,43例).采用多因素logistic回归分析NSLN转移的独立影响因素.比较两组随访期无病生存率和总生存率.结果 两组患者脉管浸润比例、肿瘤位置、SLN未转移数、肿瘤直径比较差异均有统计学意义(P＜0.05).多因素logistic回归分析结果显示,肿瘤直径越大是NSLN转移的独立危险因素(P＜0.05),SLN未转移数越多是NSLN转移的独立保护因素(P＜0.05).123例患者随访1～108个月,仅转移组中出现2例原发第二恶性肿瘤,2例发生远处转移.两组总生存率相仿(P＞0.05),但转移组无病生存率低于未转移组(P＜0.05).结论 肿瘤直径和SLN未转移数是1～2枚SLN宏转移且行乳房切除术的早期乳腺癌患者NSLN转移的独立预测因素.

目的 采用Meta分析的方法评价三阴性乳腺癌(TNBC)患者新辅助化疗(NAC)前Ki-67表达对病理完全缓解(pCR)的预测价值.方法 计算机检索PubMed、The Cochrane Library、中国知网、维普、中国生物医学文献数据库、万方数据库,采用主题词和自由词相结合的方式,筛选出TNBC患者NAC前Ki-67表达与pCR相关的文献.提取资料并进行质量评价,使用RR评价TNBC患者NAC前Ki-67表达与pCR的关系,使用Review-Manager 5.3和Stata 16.0软件进行Meta分析.结果 共纳入11篇文献,包含1020例患者,纳入研究均为回顾性队列研究.Meta分析结果显示:NAC前Ki-67高表达的TNBC患者病理完全缓解率(pCRR)明显高于Ki-67低表达患者(RR=2.63,95％CI:2.02～3.44).以Ki-67表达阈值进行亚组分析,结果显示在≥30％亚组和<30％亚组,Ki-67高表达患者pCRR均高于Ki-67低表达患者(RR=3.05和1.96,95％CI:2.19～4.23和1.23～3.12).结论 TNBC患者NAC前Ki-67表达可以作为pCR的预测因素.

There is no strong evidence indicating the optimal treatment for breast cancer (BC) and no specific prognostic model. The aim of this study was to establish nomograms to predict the overall survival (OS) of BC patients receiving chemoradiotherapy and surgery, thereby quantifying survival benefits and improving patient management. A total of 1877 patients with primary nonmetastatic BC who received chemoradiotherapy and surgery from 2010 to 2019 were identified from the Surveillance, Epidemiology and End Results (SEER) database as the training cohort, 804 as the internal validation cohort, and 796 patients from the First Affiliated Hospital of Zhengzhou University (n=324) and Jiaxing Maternal and Child Health Hospital (n=472) as the external validation cohort. Least absolute shrinkage and selection operator (LASSO), univariate, and multivariate Cox regression analyses were performed in the training cohort to determine independent prognostic factors for BC, and a nomogram was constructed to predict 3-year, 5-year, and 8-year OS. The final model incorporated 7 factors that significantly affect OS: race, location, positive regional nodes, T stage, N stage, subtype, and grade. The calibration curves showed good consistency between the predicted survival and actual outcomes. Time-dependent receiver operating characteristic (ROC) curves and the time-dependent area under the curve (AUC) confirmed that the accuracy and clinical usefulness of the constructed nomograms were favorable. Decision curve analysis (DCA) and net reclassification improvement (NRI) also demonstrated that this nomogram was more suitable for clinical use than the 7th American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging system and the previous prediction model. In the training cohort and the internal validation cohort, the concordance indices (C-index) of the nomogram for predicting OS (0.723 and 0.649, respectively) were greater than those of the 7th AJCC TNM staging system and the previous prediction model. In addition, based on Kaplan-Meier (K-M) survival curves, the survival differences among different risk stratifications were statistically significant, indicating that our risk model was accurate. In this study, we determined independent prognostic factors for OS in patients with primary nonmetastatic BC treated with chemoradiotherapy and surgery. A new and accurate nomogram for predicting 3-, 5-, and 8-year OS in this patient population was developed and validated for potential clinical applicability.

目的 探讨三阴性乳腺癌(TNBC)患者临床病理特征与腋窝淋巴结转移(ALNM)的关系.方法 回顾性分析95例接受前哨淋巴结活检(SLNB)或腋窝淋巴结清扫的TNBC患者的临床资料,依据是否有ALNM分为转移组(22例)和未转移组(73例).采用单因素分析和多因素logistic回归分析ALNM的影响因素,绘制ROC曲线分析相关指标对ALNM的诊断价值.结果 转移组肿瘤直径和年龄＞50岁、组织学分级Ⅲ级、有脉管浸润的患者比例大于未转移组(P＜0.05).多因素logistic回归分析结果显示,肿瘤直径和脉管浸润是ALNM的独立影响因素(P＜0.05).肿瘤直径与脉管浸润联合因子诊断ALNM的AUC为0.901(P＜0.05),当取最佳诊断界值2.45时,其诊断的灵敏度为95.5％,特异度为78.1％.结论 根据TNBC患者的临床病理特征可能豁免SLNB.肿瘤直径联合脉管浸润对ALNM有一定的诊断价值.

目的 探讨激素受体(HR)阳性、人类表皮生长因子受体2(HER-2)阴性绝经后早期乳腺癌患者21基因检测结果与临床病理特征的关系.方法 选取2018年8月1日至2022年8月31日嘉兴市妇幼保健院收治的行手术治疗的HR阳性、HER-2阴性的绝经后早期乳腺癌患者45例.患者乳腺癌组织石蜡标本送至专业检验中心进行21基因检测,根据21基因检测的复发风险评分(RS)分为21基因检测结果高危(RS≥26分)患者15例,低危(RS＜26分)患者30例.比较高危患者与低危患者临床病理特征;分析患者21基因检测结果的影响因素;分析筛选出的独立影响因素对患者21基因检测结果的预测价值.结果 高危患者与低危患者年龄、BMI、伴发慢性疾病、组织学类型、雌激素受体表达、孕激素受体表达、HER-2表达情况比较差异均无统计学意义(均P＞0.05),而肿瘤直径、组织学分级、神经脉管浸润、Ki-67表达情况比较差异均有统计学意义(均P＜0.05).logistic回归分析显示,Ki-67高表达是21基因检测结果高危的独立危险因素(OR=101.013,95％CI:6.478～1 575.105,P＜0.05).ROC曲线分析显示,Ki-67表达情况预测患者21基因检测结果的最佳截断值为17.5％,AUC为0.928(95％CI:0.820～1.000,P＜0.05),灵敏度为0.933,特异度为0.900,有较好的预测价值.结论 HR阳性、HER-2阴性绝经后早期乳腺癌患者21基因检测结果高危患者Ki-67高表达概率较高.临床可筛选Ki-67高表达的患者进行21基因检测,Ki-67低表达的患者可能复发风险较低,或可避免21基因检测,仅进行内分泌治疗,进而减轻低复发风险患者的医疗负担.

目的:探讨miRNA-105在乳腺癌组织的表达及对乳腺癌细胞增殖的影响.方法:通过荧光定量PCR验证15对乳腺癌组织及癌旁组织miRNA-105的表达水平.使用miRNA抑制剂干扰乳腺癌细胞中miRNA-105的表达,QPCR检测miRNA-105的表达水平;CCK-8检测细胞增殖;进行生存分析研究miRNA-105对预后的影响.结果:miRNA-105在乳腺癌组织及细胞中显著高表达(P<0.001).抑制miRNA-105表达后,细胞增殖能力下降.结论:miRNA-105在乳腺癌组织及MCF-7细胞中高表达,发挥癌基因作用,其抑制剂能够抑制乳腺癌MCF-7细胞的增殖能力.

Background: Neoadjuvant chemotherapy can cause certain damage to patients’ physiological function. Therefore, we suspected that the sensitivity to propofol would also be altered by neoadjuvant chemotherapy. We aimed to compare the ED50 for inducing loss of consciousness (LOC) in patients with and without preoperative neoadjuvant chemotherapy. Methods: Sixty-two patients were randomized to receive neoadjuvant chemotherapy (group N) or not (group C) 10 to 15 days before elective modify radical mastectomy. The up-down method was used to determine the ED50 of propofol. Patients in each group received an initial dose of 4.0 μg/mL of propofol and a variable dose (increments or decrements) of 0.4 μg/mL of propofol based on the effective or ineffective response of the prior patient. The effective dose of propofol for induction of LOC in 50% patients was calculated and compared. Results: The EC50 and 95% confidence intervals (95%CI) of propofol in the two groups were 3.27 μg/mL (95%CI, 3.09～3.43 μg/mL) and 3.33μg/mL (95%CI, 3.19～3.47 μg/mL) for patients undergoing elective modified radical mastectomy with and without neoadjuvant chemotherapy respectively. Thus, there was no difference in the EC50s between the two groups, P = 0.55. Conclusions: Under the condition of this study, we found the EC50s of propofol for induction of LOC were 3.27 and 3.33 μg/mL for patients undergoing elective modified radical mastectomy in the presence or absence of neoadjuvant chemotherapy. We do not recommend reducing the dose of propofol for induction of LOC in patients with neoadjuvant chemotherapy.

目的 探讨乳腺基底细胞型导管内原位癌的组织病理学形态、免疫组化及其诊断和鉴别诊断.方法 对7例乳腺基底细胞型导管内原位癌患者的临床组织病理学和免疫组化特征进行观察,并复习相关文献.结果 7例乳腺基底细胞型导管内原位癌,肿瘤长径0.8～3.8cm,镜下瘤细胞为实体型、乳头状或筛状型,可见点状坏死及中央坏死(粉刺型),筛状型的筛孔多呈圆形,腔缘光滑,细胞无极性分化.7例中免疫组化检测CK5/6(+)7例,CK14(+)、CK17(+)和P63(+)各6例、EGFR(+)5例、CD117(+)4例,Ki-67阳性(+30％～60％).结论 乳腺基底细胞型导管内原位癌是一种特殊类型的导管内原位癌(高级别),具有基底细胞标记阳性的特征,推测其可能是基底细胞型乳腺癌(basal-like breast carcinoma,BLBC)的前驱病变.

对未出现腋窝淋巴结转移的早期乳腺癌患者行腋窝淋巴结清扫,不仅不会提高生存率、降低复发率,反而增加了术后并发症[1,2].保留腋窝淋巴结可有效缓解淋巴管破坏引起的淋巴水肿、感觉异常等并发症,提高患者的生活质量.前哨淋巴结(sen-tinel lymph node,SLN)可准确反映腋窝淋巴结状况,前哨淋巴结活检(sentinel lymph node biopsy,SL-NB)已迅速替代腋窝淋巴结清扫(axillary lymph node dissection,ALND)成为临床腋淋巴结阴性乳腺癌患者的标准处理模式[3].本次研究探讨纳米炭混悬液应用于乳腺癌前哨淋巴结活检的意义.现报道如下.

目的 探讨空芯针穿刺活检术(core needle biopsy,CNB)与微创旋切活检术(vacuum-assisted biopsy,VAB)对有活检指征患者的临床诊断价值,比较两种方法在乳腺疾病诊断、免疫组织化学判断及荧光原位杂交(fluorescence in situ hybridization,FISH)检验等方面的差异.方法 选取150例行CNB的患者,同时选择150例年龄、肿块大小和乳腺影像报告和数据系统(breast imaging reporting and data system,BI-RADS)分类情况相似的行VAB的病例进行配对分析,统计两种活检方式诊断的准确率及术前和术后免疫组织化学、FISH检验的符合率,同时比较两种活检方式术中和术后并发症情况.结果 VAB组与CNB组术前、术后病理诊断一致率分别为98.0％和96.7％(P=0.395).VAB组65例导管内原位癌(ductal carcinoma in situ,DCIS)中5例为浸润性导管癌(invasive ductal carcinoma,IDC),CNB组64例DCIS中22例为IDC(P=0.034).VAB组未发现非典型性导管增生(atypical ductal hyperplasia,ADH)病例的鉴定误差,CNB组2例ADH中1例为IDC(P=0.021).VAB比CNB需要更长的操作时间(P＜0.01),疼痛评分报告VAB的疼痛程度与CNB相似(P =0.962).结论 空芯针穿刺活检术是一种简便易行、安全且并发症少的可靠诊断技术,值得临床推广应用.而微创旋切活检术针体更粗、取材更充分,可能在免疫组织化学的判断上更具优势,病理符合率也更加明显,特别是对于IDC低估率明显降低.

Objective To analyze the related factors of sentinel lymph node biopsy(SLNB)success rate in breast cancer.Methods 217 cases of breast cancer patients treated with SLNB with methylene blue dye were selected in Jiaxing Maternal and Child Health-Care Center from January 2015 to October 2016. The factors correlated with the success of SLNB were explored.Results Through univariate analysis,blue dye success was associated with:pathological examination of tumor size(P=0.033),location of tumor(P=0.027),ultrasound BI-RADS classification(P<0.001), the expression of ER(P<0.001),the expression of PR(P=0.005).In multivariate analysis,SLNB success was associated with tumor location (P=0.031),BI-RADS classification(P=0.004)and expression of ER(P=0.007).Conclusion Location of tumor(P=0.027),ultrasound BI-RADS classification and the expression of ER may be the factors affect the success of SLNB in breast cancer.

Introduction Neoadjuvant chemotherapy has many advantages, including shrinking the tumor volume, down-staging the tumor, reducing the scope of operation, decreasing the degree of trauma, providing evidence for postoperative chemotherapy and even avoiding mastectomy [1]. However, a certain degree changes of physiological are associated with neoadjuvant chemotherapy, such as immune function and hepatic function [2]. Moreover, studies reported that cognitive function declined after neoadjuvant chemotherapy in patients with breast cancer. Therefore, we suspect that the sensitive to general agents would be also changed of patients after neoadjuvant chemotherapy. This study aimed to determine the minimum effective concentration represented by the median effective concentration (EC50, which means the concentration that would be necessary to provide effective induction for 50% of the patients treated) of propofol for inducing loss of consciousness (LOC), using up-down allocation method.

OBJECTIVE To explore the distribution and drug resistance of pathogen infections in patients with lacta-tion suppurative mastitis.METHODS A total of 120 patients with lactation suppurative mastitis who were treated in the hospital from Jan 2013 to Jul 2016 were recruited as the study objects,and the distribution and drug resist-ance of the pathogens causing infections were observed.RESULTS Totally 75 strains of pathogens were isolated from specimens of the 120 patients,with the isolation rate 62.5%,of which 66(88.0%)were Staphylococcus aureus.Among the isolated S.aureus strains,24 were multidrug-resistant methicillin-resistant S.aureus,with the isolation rate 36.4%.The drug susceptibility testing indicated that the drug resistance rate of the 66 S.aureus iso-lates to penicillin was the highest(96.9%),the drug resistance rates to vancomycin and ciprofloxacin were the lowest(0%);the drug resistance rates of the 24 strains of methicillin-resistant S.aureus to penicillin,oxacillin and amoxacillin were the highest(100.00%),and the drug resistance rates to vancomycin,teicoplanin and sulfa-methoxazole-trimethoprim were lowest(0).CONCLUSION The S.aureus is the predominant species of pathogens causing infections in the patients with suppurative mastitis,and there is certain proportion of multidrug-resistant strains,thus,it is the key to reasonably use antibiotics so as to improve the therapeutic effect.

Objective: To evaluate the efficacy of adjuvant endocrine therapy (AET) in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy (NAC). Methods: One hundred and six patients who presented with hormone receptor (HR)-positive breast cancer at diagnosis and turned to HR-negative after NAC during December 2000 and December 2013 in Jiaxing Maternity and Child Health Care Hospital were retrospectively identified. Kaplan-Meier analysis and log-rank test were used for univariate analyses of factors related to disease free survival (DFS) and overall survival (OS). Multivariate analysis was carried out using the Cox proportional hazards model in patients with DFS and OS. Results: All the patients were categorized into two groups on the basis of the administration of AET:61 AET-administered patients (57.5%) and 45 AET-naïve patients (42.5%). After a median follow-up of 68 months (range 14-103 months), human epidermal growth factor receptor 2 (HER-2) status, initial clinical stage, pathological axillary lymph node status and the use of AET were identified as the variables affecting DFS and OS (all P<0.05). Patients treated with AET had a significantly improved 5-year DFS rate when compared with that without AET (77.1% vs 53.5%,P<0.05). The 5-year OS of AET-administered patients was also better than that of AET-naïve patients (80.9% vs 71.0%,P<0.05). Cox regression analysis showed that AET-administered or not was the independent predictor for 5-year DFS (HR=2.096, 95% CI:1.081-4.065, P<0.05). Conclusion: Patients with HR altered from positive to negative after NAC may still gain benefit from AET.